A 42-year-old woman with multiple uterine fibroids and menorrhagia is not a surgical candidate due to severe comorbidities. She requires long-term medical management (>6 months) to control symptoms and avoid transfusion. Which drug is preferred for prolonged use in this scenario?

Explanation

## Prolonged Medical Management of Symptomatic Fibroids ### Clinical Context: Why Add-Back Therapy? When GnRH agonist therapy must extend beyond 6 months (due to surgical ineligibility, patient preference, or perimenopausal status), add-back therapy is essential to: 1. Prevent cumulative bone loss (1–3% per month without add-back) 2. Reduce vasomotor symptoms (hot flushes, night sweats) 3. Maintain vaginal health and mood stability 4. Preserve fibroid shrinkage (add-back does not reverse it) **Key Point:** Leuprolide + add-back (norethisterone 5 mg daily OR conjugated estrogens 0.625 mg daily + medroxyprogesterone 5 mg daily) is the evidence-based regimen for prolonged GnRH agonist use in fibroids. ### Comparison of Long-Term Medical Options | Agent | Mechanism | Fibroid Shrinkage | Bone Safety | Menorrhagia Control | Duration Limit | Use in Fibroids | |---|---|---|---|---|---|---| | **GnRH agonist + add-back** | Hypogonadism + HRT | Yes (20–40%) | Safe if add-back given | Excellent | Unlimited with add-back | **Gold standard for prolonged use** | | Danazol | Androgen + progestin | Modest | Acceptable | Moderate | 6–12 months | Rarely used now (virilization, lipid effects) | | High-dose norethisterone | Progestin | Minimal | Good | Moderate | Indefinite | Adjunctive only; insufficient alone | | Methotrexate | Antimetabolite | No | Poor | No | Not applicable | **Contraindicated** (teratogenic, no efficacy) | **High-Yield:** The add-back regimen (norethisterone 5 mg daily) is preferred over conjugated estrogens in women with fibroids because it provides bone protection while avoiding estrogen-driven fibroid growth. ### Why Leuprolide + Add-Back Is Superior for This Patient - ✓ Proven menorrhagia control - ✓ Bone safety with prolonged use - ✓ Symptom relief (dysmenorrhea, pelvic pressure) - ✓ Avoids transfusion risk - ✓ Can be used indefinitely if add-back given **Clinical Pearl:** Baseline DEXA scan and repeat DEXA at 12–24 months is recommended for women on prolonged GnRH agonist therapy to monitor bone density. [cite:Berek & Novak's Gynecology 16e Ch 18; ACOG Practice Bulletin 228]